Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib and Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme
NCT00068770Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Oct 2003
- Primary completion
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of celecoxib oral solution in glioblastoma multiforme (GBM) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Pharmacokinetics of Celecoxib at 6 weeks. Started Oct 2003; status: terminated.
02
Drugs
celecoxib oral solution
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00068770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00068770.